Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-387 in Healthy Volunteers (Fasting)
NCT06399055Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of D484 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the concentration-time curve from time 0 to the last measurable concentration at 48 hours and Maximum plasma concentration at 48 hours. Started Sep 2022; status: completed.
02
Drugs
D484
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06399055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399055.